Ohmeda: Corporate Restructuring 90's Style
Far more than a simple downsizing to increase productivity, Ohmeda's experience underscored that the challenges product companies confront embrace new ways of relating to customers, of valuing technology, and most fundamentally, of valuing company assets.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.